In HCC models, losartan has been shown to suppress Ang II–induced VEGF expression and to sensitise tumour cells to the multi‐kinase inhibitor lenvatinib, suggesting a role in overcoming autocrine VEGF‐mediated resistance [42]. This evidence concerns the gene VEGFA and hepatocellular carcinoma.